High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.

Abstract

Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.

• Authors: T H Brannagan 3rd, A Pradhan, T Heiman-Patterson, A C Winkelman, M J Styler, D L Topolsky, P A Crilley, R J Schwartzman, I Brodsky, D E Gladstone
• Journal: Neurology (Neurology) Vol. 58 Issue 12 Pg. 1856-8 (Jun 25 2002) ISSN: 0028-3878 [Print] United States
• PMID: 12084892 (Publication Type: Journal Article)

Chemical References

• Immunosuppressive Agents
• Cyclophosphamide

Topics

• Adult
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Immunosuppressive Agents (administration & dosage)
• Male
• Middle Aged
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (drug therapy, immunology, physiopathology)
• Stem Cell Transplantation
• Stem Cells (immunology)
• Treatment Outcome